Maintenance Factors Affecting Increased Lutetium-177 Production
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Nuclear Engineering and Radiation Science"
DOI: 10.1115/1.4049344
Abstract: With lutetium (Lu-177) demand forecasted to increase following the conclusion of clinical trials and product registration in key jurisdictions, manufacturers are seeking to improve their production outputs. Naturally, the question falls to operation and maintenance… read more here.
Keywords: maintenance factors; production; maintenance; lutetium 177 ... See more keywords
Visual deficit possibly caused by lutetium-177 PSMA treatment
Sign Up to like & getrecommendations! Published in 2018 at "BMJ Case Reports"
DOI: 10.1136/bcr-2018-225508
Abstract: This report describes a case of a 54-year-old man who underwent lutetium-177-PSMA therapy in the setting of metastatic castration-resistant prostate cancer (mCRPC) in the University Medical Center Utrecht. Following administration of the second cycle, patient… read more here.
Keywords: deficit possibly; 177 psma; lutetium 177; psma ... See more keywords
Abstract CT194: ETCTN 10388: a first in human phase I trial of triapine and lutetium Lu 177 DOTATATE in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct194
Abstract: Background: Radiation is a potent inducer of DNA double-strand breaks, and ribonucleotide reductase (RNR) is the rate-limiting enzyme in the synthesis and repair of DNA, making RNR-targeted therapy a rationale therapeutic strategy for radiosensitization. ETCTN… read more here.
Keywords: lutetium 177; dotatate; 177 dotatate; triapine ... See more keywords
Lutetium Lu 177 Dotatate Approved by FDA.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-021
Abstract: The FDA recently approved the radiopharmaceutical lutetium Lu 177 dotatate to treat patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The approval was based on results of the phase III NETTER-1 trial. read more here.
Keywords: approved fda; 177 dotatate; dotatate approved; lutetium 177 ... See more keywords
Inter-comparison of quantitative imaging of lutetium-177 (177Lu) in European hospitals
Sign Up to like & getrecommendations! Published in 2018 at "EJNMMI Physics"
DOI: 10.1186/s40658-018-0213-z
Abstract: BackgroundThis inter-comparison exercise was performed to demonstrate the variability of quantitative SPECT/CT imaging for lutetium-177 (177Lu) in current clinical practice. Our aim was to assess the feasibility of using international inter-comparison exercises as a means… read more here.
Keywords: imaging lutetium; inter comparison; quantitative imaging; lutetium 177 ... See more keywords
Lutetium Lu 177 vipivotide tetraxetan for prostate cancer.
Sign Up to like & getrecommendations! Published in 2023 at "Drugs of today"
DOI: 10.1358/dot.2023.59.1.3476574
Abstract: On March 23, 2022, the U.S. Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan), also known as 177Lu-PSMA-617, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who… read more here.
Keywords: 177 vipivotide; prostate; lutetium 177; vipivotide tetraxetan ... See more keywords
Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15041240
Abstract: Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine and oncology, allowing for personalized medicine. Since the first market authorization in 2018… read more here.
Keywords: therapeutic optimization; lutetium 177; safety therapeutic; based radiopharmaceuticals ... See more keywords